Protective Role of the Podocyte IL-15 / STAT5 Pathway in Focal Segmental Glomerulosclerosis

Protective Role of the Podocyte IL-15 / STAT5 Pathway in Focal Segmental Glomerulosclerosis

Introduction: During glomerular diseases, podocyte-specific pathways can modulate the intensity of histological disease and prognosis. The therapeutic targeting of these pathways could thus improve the management and prognosis of kidney diseases. The Janus Kinase/Signal Transducer and Activator of T...

Full description

Saved in:
Bibliographic Details
Main Authors: Aïssata Niasse, Kevin Louis, Olivia Lenoir, Chloé Schwarz, Xiaoli Xu, Aymeric Couturier, Hélène Dobosziewicz, Anthony Corchia, Sandrine Placier, Sophie Vandermeersch, Lothar Hennighausen, Perrine Frère, Pierre Galichon, Brigitte Surin, Souhila Ouchelouche, Liliane Louedec, Tiffany Migeon, Marie-Christine Verpont, Nadir Yousfi, David Buob, Yi-Chun Xu-Dubois, Hélène François, Eric Rondeau, Laurent Mesnard, Juliette Hadchouel, Yosu Luque
Format: Article
Language:English
Published: Elsevier 2024-04-01
Series:Kidney International Reports
Subjects:
autophagy
cell signaling
cytokines
focal segmental glomerulosclerosis
IL-15
podocyte
Online Access:http://www.sciencedirect.com/science/article/pii/S246802492400010X
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Introduction: During glomerular diseases, podocyte-specific pathways can modulate the intensity of histological disease and prognosis. The therapeutic targeting of these pathways could thus improve the management and prognosis of kidney diseases. The Janus Kinase/Signal Transducer and Activator of Transcription (JAK/STAT) pathway, classically described in immune cells, has been recently described in detail in intrinsic kidney cells. Methods: We describe STAT5 expression in human kidney biopsies from patients with focal segmental glomerulosclerosis (FSGS) and studied mice with a podocyte-specific Stat5 deletion in experimental glomerular diseases. Results: Here, we show, for the first time, that STAT5 is activated in human podocytes in FSGS. In addition, podocyte-specific Stat5 inactivation aggravates the structural and functional alterations in a mouse model of FSGS. This could be due, at least in part, to an inhibition of autophagic flux. Finally, interleukin 15 (IL-15), a classical activator of STAT5 in immune cells, increases STAT5 phosphorylation in human podocytes, and its administration alleviates glomerular injury in vivo by maintaining autophagic flux in podocytes. Conclusion: Activating podocyte STAT5 with commercially available IL-15 represents a potential new therapeutic avenue for FSGS.
ISSN:2468-0249

Similar Items